However, the ERK1/2 gene expression level was significantly higher in the running PA group receiving a daily high dose of isatin (PA-IH group) when compared with the corresponding non-running group C-IH and the control group C-V. The gene discussed is MAPK3; the disease is isolated hemihyperplasia.